Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Astellas Pharma Inc.

    PNK: ALPMY · Real-Time Price · USD
    9.25
    -0.19 (-2.01%)
    At close: May 13, 2025, 3:59 PM
    -2.01%
    Bid 9.22
    Market Cap 16.56B
    Revenue (ttm) 1,701.8B
    Net Income (ttm) 17.38B
    EPS (ttm) 0.2
    PE Ratio (ttm) 46.25
    Forward PE n/a
    Analyst n/a
    Ask 9.28
    Volume 11,328
    Avg. Volume (20D) 191,768
    Open 8.97
    Previous Close 9.44
    Day's Range 8.97 - 9.32
    52-Week Range 8.37 - 13.14
    Beta 0.14

    About ALPMY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ALPMY
    Website n/a
    Full Company Profile
    news image

    15 hours ago · zacks.com

    Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now

    Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could m...

    news image

    2 weeks ago · zacks.com

    Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

    Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    news image

    2 weeks ago · zacks.com

    Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

    Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

    news image

    2 weeks ago · seekingalpha.com

    Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript

    Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative ...

    news image

    1 month ago · seekingalpha.com

    Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward

    Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits ha...

    news image

    2 months ago · https://www.marketscreener.com

    Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

    Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (...

    Add to Watchlist